NOTCH2: Neurogenic locus notch homolog protein 2
Functions as a receptor for membrane-bound ligands Jagged-1 (JAG1), Jagged-2 (JAG2) and Delta-1 (DLL1) to regulate cell-fate determination.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on NOTCH2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Tarextumab | Phase 2 | OncoMed Pharmaceuticals | Antibody | InhibitorNeurogenic locus notch homolog protein 2 inhibitor | 0 |
- Acroosteolysis dominant type0.83
- Alagille syndrome due to a NOTCH2 point mutation0.76
- Alagille syndrome0.70
- Diffuse large B-cell lymphoma0.55
- Diabetes mellitus0.47
- Cutaneous squamous cell carcinoma0.42
- Keratoacanthoma0.42
- Prostate adenocarcinoma0.41
- Lung carcinoma0.39
- Melanoma0.38
- Prostate carcinoma0.38
- Gastric carcinoma0.38
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3407320, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q04721, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets